RenovoRx to Join Fireside Chat at A.G.P. Virtual Healthcare Showcase on May 21, 2024

RenovoRx, Inc., a clinical-stage biopharmaceutical company specializing in precision oncology therapies, announced that its Chief Executive Officer, Shaun Bagai, will participate in a fireside chat at the Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase. The event, hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P., is set to take place on Tuesday, May 21, 2024.

During the showcase, Mr. Bagai will discuss the company's recent achievements, including the successful completion of private placements in January and April 2024, which collectively raised $17.2 million in gross proceeds. This funding will enable RenovoRx to advance its pivotal Phase III TIGeR-PaC clinical trial, explore new cancer treatment indications, and expand its commercial business development opportunities.

The TIGeR-PaC study focuses on evaluating RenovoRx’s lead product candidate, RenovoGem™, in conjunction with the company’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. This trial targets the treatment of locally advanced pancreatic cancer. The next significant milestone for the TIGeR-PaC study, the second interim analysis, will be set off by the 52nd event (death) and is expected to occur in late 2024.

RenovoRx is dedicated to enhancing the outcomes of cancer treatments by developing innovative solutions through its patented TAMP™ therapy platform. This platform aims to deliver precise therapeutic doses directly to tumors, potentially reducing the systemic toxicity typically associated with intravenous therapies. The company's approach promises increased safety, better tolerance, and improved efficacy in cancer treatment.

Currently, RenovoGem™ is under investigation in a Phase III clinical trial regulated by the U.S. Food and Drug Administration (FDA). The trial is managed by the Center for Drug Evaluation and Research, a division focused on drug regulation within the FDA. RenovoGem™ is designed as a combination product that integrates a novel drug with a medical device, specifically for treating locally advanced pancreatic cancer via the TAMP™ platform.

RenovoRx is committed to revolutionizing cancer care and improving patient outcomes with its groundbreaking therapeutic technologies. Although RenovoGem™ is still in the investigational stages and has not yet received approval for commercial sale, the company is optimistic about its potential benefits and future impact on cancer treatment.

RenovoRx emphasizes its mission to transform patient lives through innovative cancer therapies, signaling a shift from traditional treatment paradigms. The company's ongoing research and clinical trials reflect its commitment to developing advanced treatment options that aim to meet high unmet medical needs in oncology.

The detailed discussion of RenovoRx's recent milestones and strategic direction during the A.G.P. Virtual Healthcare Company Showcase will provide valuable insights into the company's progress and future plans within the biopharmaceutical landscape. The event promises to shed light on RenovoRx’s efforts to address critical challenges in cancer treatment through precision medicine and innovative drug delivery systems.